IP Library Granted Patent US 7,674,802
Granted Patent B2
US 7,674,802 · App. 11/462,263 · Granted Mar 9, 2010

N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,674,802
App. No.
11/462,263
Granted
Mar 9, 2010
Kind
B2
Abstract

The present invention relates to a chemical genus of biaryl nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula: They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.

Claims (37)

1. A compound of formula:

wherein

ring (a) is chosen from bicyclic heterocyclyl and bicyclic heterocyclyl substituted with from one to three substituents independently selected from the group consisting of halogen, hydroxyl, loweralkyl, loweracyl, loweralkoxy, fluoroloweralkyl, fluoroloweralkoxy, formyl, cyano, nitro and oxo, said bicyclic heterocyclyl and substituted bicyclic heterocyclyl is chosen from at least one of indole, indazole, and isoindole;

Q is O;

n is zero or an integer from 1-4;

HET is chosen from at least one of piperidine and pyrrolidine; and

taken together ZW is H or

Z is (CH 2 ) 0-3 ; and

W is selected from acyl, hydroxyl, carboxyl, amino, carboxamido, sulfonamide, aminoacyl, —COOalkyl, —CHO, and —C(O)fluororalkyl, wherein the acyl is a group from 1 to 8 carbon atoms.

2. A compound according to claim 1 of formula:

wherein R 2 and R 3 each are independently selected from the group consisting of H, halogen, hydroxyl, loweralkyl, loweracyl, loweralkoxy, fluoroloweralkyl, fluoroloweralkoxy, formyl, cyano, and nitro; and

n is 1, 2 or 3.

3. A compound according to claim 1 , wherein

HET is chosen from piperidine and pyrrolidine;

and

W is selected from the group consisting of acyl, hydroxyl, carboxyl, amino, carboxamide, and aminoacyl.

4. A compound according to claim 3 of formula

wherein

R 2 is chosen from H, hydroxyl, and halogen;

R 3 chosen from H and halogen;

Z is chosen from (CH 2 ) 0-3 and

W is selected from the group consisting of acyl, hydroxyl, carboxyl, amino, carboxamido, aminoacyl, and COOalkyl.

5. A compound according to claim 1 of formula:

wherein

R 2 is selected from the group consisting of H, loweralkyl, fluoroloweralkyl, and oxo;

R 3 is selected from the group consisting of H, halogen, loweralkyl, loweracyl, loweralkoxy, fluoroloweralkyl, fluoroloweralkoxy, formyl, cyano, and nitro; and

n is from 1-3.

6. A compound according to claim 5 , wherein

HET is chosen from piperidine and pyrrolidine;

and

W is selected from the group consisting of acyl, hydroxyl, carboxyl, amino, carboxamide, and aminoacyl.

7. A compound according to claim 1 of formula:

wherein

Y is N or CR 5;

R 7 is chosen from H and loweralkyl; and

R 5 is chosen from H and loweralkyl.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound according to claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2010
From: DECODE GENETICS, INC.
To: DECODE GENETICS, EHF
Reel/Frame 023734/0098 →
GRANT OF PATENT SECURITY INTEREST Recorded Nov 12, 2009
From: DECODE GENETICS EHF (IN ICELANDIC: ISLENSK ERFDAGREINING EHF)
To: SAGA INVESTMENTS LLC
Reel/Frame 023510/0243 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2006
From: SANDANAYAKA, VINCENT; SINGH, JASBIR; ZHAO, LEI; GURNEY, MARK E.
To: DECODE GENETICS, INC.
Reel/Frame 018579/0715 →